San Francisco

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Chronic lymphocytic leukaemia1 trial
• Diffuse large B-cell lymphoma1 trial
• Follicular lymphoma1 trial
• Mantle cell lymphoma1 trial
• Melanoma1 trial

Phase

• Phase 11 trial
• Phase 1/21 trial
• Phase 21 trial

Status

• Active, not recruiting2 trials
• Completed1 trial

Lead sponsor

• Juno Therapeutics, a Subsidiary of Celgene2 trials
• Bristol-Myers Squibb1 trial

Running trials

• Active, not recruiting

  A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

  NCT06101134· Phase 2· Bristol-Myers Squibb· Source

• Active, not recruiting

  Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

  NCT03331198· Phase 1/2· Juno Therapeutics, a Subsidiary of Celgene· Source

Closed trials

• Completed

  Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

  NCT02631044· Phase 1· Juno Therapeutics, a Subsidiary of Celgene· Source